AQ4N: a new approach to hypoxia-activated cancer chemotherapy

• Published in: British journal of cancer Vol. 83; no. 12; pp. 1589 - 1593
• Main Authors: PATTERSON, L. H, MCKEOWN, S. R
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.12.2000
• Subjects: Animals; Anthraquinones - therapeutic use; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Cancer research; Cancer therapies; Cell cycle; Cell division; Cell Hypoxia; Chemotherapy; Cytotoxicity; Humans; Hypoxia; Medical research; Medical sciences; Mini-Review; Neoplasms - drug therapy; Neoplasms, Experimental - drug therapy; Pharmacology. Drug treatments; Phosphates; Physical properties; Prodrugs - therapeutic use; Radiation-Protective Agents - therapeutic use; Toxicity; Tumors; Antineoplastic agent; DNA topoisomerase (ATP-hydrolysing); Oxygen; Anthraquinone derivatives; Enzyme; Rodentia; Enzyme inhibitor; Prodrug; Malignant tumor; Vertebrata; Chemotherapy; Isomerases; Mammalia; Treatment; Bioreductive drug; Mouse; Animal; Hypoxia

Preclinical studies demonstrate that in vivo AQ4N enhances the anti-tumour effects of radiation and chemotherapeutic agents with a dose-modifying factor of approximately 2.0. With careful scheduling no, or very little, additional normal tissue toxicity should be observed. AQ4N is a bioreductive prod...